New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

Impact · against what's priced in

The long-term pooled analysis for TransCon PTH provides strong clinical validation of renal function improvements and patient independence from conventional therapy, supporting a competitive advantage in the hypoparathyroidism market. While the data is positive, the primary value is the confirmation of sustained efficacy and safety over three years, which reinforces the drug's commercial viability.

ASND+0.60

No priced-in read yet